

This is the first PANNA newsletter, which will also be available at the website: www.pannastudy.com

A newsletter will be issued once per 3 months to update you on the status of the study regarding centres participating and inclusions of patients per drug.

Centres

All centres in *The Netherlands* (RUNMC Nijmegen; Erasmus Rotterdam; AMC Amsterdam) are open for inclusion.

Spain: Badalona is open for inclusion and is about to include the first patient.

UK: waiting for local approvals, after that all centres (C&W hospital; St Mary's Hospital; St George's hospital) can start inclusions (also including efavirenz as a compound).

Italy: ethics approval is on the way, hoping to include the first patient in November.

Germany: submission is on the run.

Canada: submissions will follow after information on the grant.

Portugal: submission will be discussed in November.

Other centres (*Ireland; Switzerland; France*) will follow and will be contacted by Angela as soon as the above mentioned centres have started.

Inclusions

No formal inclusions yet, but planned in Rotterdam, Spain and Italy.

However, dr Teresa Branco in Portugal has collected curves (3rd trimester and post partum) of a pregnant woman using raltegravir. Samples will be analyzed soon.

Next steps

- Contracts between the Radboud University Nijmegen Medical Centre and all the centres participating.
- First inclusion!
- 4 countries open for inclusion prior to 2010, all others in 2010.
- Investigator meeting in June 2010, Paris.

List of compounds under investigation

panna

Etravirine, Intelence, TMC125
Emtricitabine, Emtriva or FTC
Tenofovir, Viread, TDF
Atazanavir, Reyataz
Fosamprenavir, Telzir, FPV
Darunavir, Prezista, TMC114
Tipranavir, Aptivus, TPV
Indinavir, Crixivan
Raltegravir, Isentress
Enfuvirtide, Fuzeon
Maraviroc, Celsentri

Efavirenz, Stocrin, EFV; UK only

If you are attending the EACS in Cologne and want to discuss issues regarding the PANNA study, please contact me. I will not attend the meeting, but I can come over to Cologne, which is not far from Nijmegen. David Burger will also attend the meeting.

Looking forward to the first inclusion!

Angela Colbers
Project manager

E-mail:
A.Colbers@akf.umcn.nl

HIVPharmacology@akf.umcn.nl
Radboud University Nijmegen Medical Centre, Internal postal code 864,
Department of Clinical Pharmacy, P.O. Box 9101, 6500 HB Nijmegen

Phone: + 31 (0)24 - 361 64 05
Fax: + 31 (0)24- 366 87 55